Multivalent fibronectin-integrin binding compositions and methods of use thereof

• US 10,450,349 B2
• Filed: 03/03/2017
• Issued: 10/22/2019
• Est. Priority Date: 03/04/2016
• Status: Active Grant

• Current Assignee: Purdue Research Foundation (Purdue University)
• Original Assignee: Purdue Research Foundation (Purdue University)
• Inventors: Aguilar, Ruben Claudio, Ratliff, Timothy L.
• Primary Examiner(s): Skowronek, Karlheinz R.
• Assistant Examiner(s): Kader, Khalid
• Application Number:
  US15/448,772
• Publication Number:
  US 20170252459A1
• Time in Patent Office: 963 Days
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 14/70546 Integrin superfamily
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: G01N 33/48 Biological material, e.g. blood, urine G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence; Haemocytometers counting blood corpuscules distributed over a surface by scanning the surface G06M11/02
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/84 involving inorganic compounds or pH

Abstract

The invention provides multivalent fibronectin-integrin binding compositions and methods of use thereof. In certain embodiments, the invention provides peptide compositions that include at least two fibronectin binding peptides coupled together as a cancer therapeutic or a diagnostic tool.

Claims

1. A peptide composition comprising a peptide of an amino acid sequence selected from the group consisting of SEQ ID NOs:

1-39, a combination of any of those sequences, or a pharmaceutically acceptable salt thereof.

2. The peptide composition according to claim 1, wherein the peptide comprises a plurality of an amino acid sequence selected from the group consisting of SEQ ID NOs:

1-39, a combination of any of those sequences, or a pharmaceutically acceptable salt thereof.

3. The peptide composition according to claim 1, further comprising a cytotoxic agent.

4. The peptide composition according to claim 3, wherein the cytotoxic agent is an anti-cancer agent.

5. The peptide composition according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

6. The peptide composition according to claim 5, wherein the pharmaceutically acceptable carrier is a liposome.

7. A method for targeting or identifying cancer cells wherein cancerous cells express a component that may be bound by fibronectin/integrin binding peptides, the method comprising the step of administering to a subject of a peptide composition according to claim 1, wherein a label for identification is coupled to the peptide composition.

9. A method for treating a cancer wherein cancerous cells express a component that may be bound by fibronectin/integrin binding peptides, the method comprising the step of administering to a patient of said cancer therapeutically effective amount of a peptide composition according to claim 1, wherein an anti-cancer agent is coupled to the peptide composition.

10. The method according to claim 9, wherein the cancer is a bladder cancer.

11. The method according to claim 9, further comprising the step of administrating a therapeutically effective amount of another anti-cancer agent to the patient of said cancer.

8. A method for targeting or identifying cancer cells wherein cancerous cells express a component that may be bound by fibronectin/integrin binding peptides, the method comprising the step of administering to a subject of a peptide composition comprising a peptide of an amino acid sequence selected from the group consisting of SEQ ID NOs:

1-39, and a combination of any of those sequences, wherein a label for identification is coupled to the peptide composition.

12. (Withdrawn, Currently Amended) A method for treating a cancer wherein cancerous cells express a component that may be bound by fibronectin/integrin binding peptides, the method comprising the step of administering to a patient of said cancer therapeutically effective amount of a peptide composition comprising a peptide of an amino acid sequence selected from the group consisting of SEQ ID NOs:

1-39, and a combination of any of those sequences, wherein an anti-cancer agent is coupled to the peptide composition.

13. The method according to claim 12, wherein the cancer is a bladder cancer.

14. The method according to claim 12, further comprising the step of administrating a therapeutically effective amount of another anti-cancer agent to the patient of said cancer.